MedInCell Stock Up 2.85% at €25.22, Challenging Technical Resistance
The Montpellier-based biotech regains momentum in the mid-afternoon, following the CAC 40 which is up by 0.49% during the session. The stock is approaching a technical threshold observed for several weeks, just over a month before the annual results are published.
MedInCell gains 2.85% to €25.22 during the session, after closing the previous day at €24.52. This movement largely offsets Monday's decline, bringing the weekly performance to nearly 6%. The price is immediately in contact with the resistance at €25.12, identified by market data. It also flirts with the upper limit of the Bollinger Bands, set at €25.61, placing the stock at the high end of its short-term technical range. The RSI at 56 remains in a neutral zone, without a marked overbought signal. The stock also moves back above its 200-day moving average (€24.23), a configuration it had briefly tested in mid-April. Over one year, the stock maintains a gain of nearly 63%.
Olanzapine LAI in Focus Ahead of Annual Publication
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The financial calendar sets several concrete dates for the stock. A research and development day is scheduled for May 12, 2026, followed by the publication of annual results on June 16, 2026 (fiscal year April 2025 - March 2026). The general assembly will be held on September 10. During the semi-annual publication covering the period from April to September 2025, the company indicated it expects an acceleration of its revenues in the coming years, driven by Olanzapine LAI. The NDA submitted for this candidate is among the main opportunities identified by the group, alongside the upward revision of the 2025 sales forecasts for UZEDY® by its partner Teva, now expected between $190 and $200 million versus $160 million previously. The company also cited among its risks the dependence on commercialization by Teva and the regulatory uncertainty regarding upcoming approvals. The next concrete appointment remains the R&D day on May 12, followed a month later by the annual accounts.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
